ABBV has added another $1.60 since Sunday's recovery note and now trades at $256.10 — six days from a Q2 earnings print that has become the most anticipated catalyst on the pharma calendar this month.
The analyst upgrade wave, which defined the past two weeks, landed one more volley this morning. Canaccord Genuity raised its target to $282 from $273, maintaining Buy — the most recent in a sequence of ten target lifts since July 6. The direction of travel is unambiguous: bulls at BMO ($300) and Wells Fargo ($295) sit in the highest tier, while the cautious contingent — Citigroup and UBS both holding Neutral at $260 — are now essentially at-the-money relative to where the stock is trading. The consensus mean lands at $266.89, implying roughly 4% additional upside. The core debate has not changed: bulls see a franchise-level re-rating driven by Skyrizi and Rinvoq momentum plus a pipeline of over 90 compounds; bears flag concentration risk, Imbruvica's competitive pressures, and the question of whether valuation already prices in the good news. Forward earnings estimates remain on a strong upward trajectory — the 12-month forward EPS growth factor ranks in the 99th percentile — but the EPS surprise rank is an outlier in the other direction at just the 9th percentile, suggesting the Street has learned to set its bar high.
Positioning is as relaxed as it has been all year. Short interest has continued to drift lower on a month-over-month basis, down 22% from its late-June peak of roughly 25 million shares to just under 19.6 million now — 1.1% of the free float. That is a multi-month floor, and the direction of travel confirms that short sellers have been buyers of the recovery, not resisters of it. Borrow conditions reflect the same picture: availability is effectively unlimited, with over 1.1 billion shares available to lend, and cost to borrow has eased to 0.34% — down 26% on the week. Options traders are equally relaxed. The put/call ratio of 0.75 is fractionally below its 20-day average of 0.76, putting the z-score near zero. There is no hedging premium baked into the options market ahead of next Monday's print.
That absence of defensiveness is notable given the stock's own earnings history. The two most recent quarterly reports both produced positive first-day moves — April's Q1 print delivered a 6.9% gain, and the May update added a further 0.03%. Five-day reactions were constructive in both cases, adding 3.7% and 3.8% respectively after those prints. The market has rewarded AbbVie on each of those two occasions, and nothing in the current positioning suggests traders are bracing for a reversal of that pattern. Peers have broadly kept pace this week: AMGN gained 3.1% and HALO added 4.7%, suggesting the bid in large-cap biotech is sector-wide rather than stock-specific. GILD was the outlier, slipping 2.2% on the day.
Institutionally, the ownership picture is dominated by passive and quasi-passive flows. BlackRock added roughly 3.6 million shares in the most recent filing period to hold 8.5% of the company. Capital Research and Management made the most notable active move, adding 11.5 million shares to bring its position to 3.5%. These are supportive flows for a stock that has risen $40 from its mid-June trough, and they provide context for why the short base has found it difficult to rebuild — the demand side of the register is consistently absorbing supply.
The question that remains live heading into July 27 is whether the stock's 18% gain over the past month has pulled enough of the Q2 beat forward that the print itself needs to be exceptional to sustain the rally — or whether the Street's continued willingness to lift targets even as the stock approached $256 signals genuine conviction that the re-rating has further to run.
See the live data behind this article on ORTEX.
Open ABBV on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
